Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Receivables - Other: 2018-2019

  • Puma Biotechnology's Receivables - Other was N/A to $9.9 million in Q1 2019 from the same period last year, while for Mar 2019 it was $9.9 million, marking a year-over-year change of. This contributed to the annual value of $1.2 million for FY2018, which is N/A change from last year.
  • Per Puma Biotechnology's latest filing, its Receivables - Other stood at $9.9 million for Q1 2019, which was up 743.57% from $1.2 million recorded in Q4 2018.
  • In the past 5 years, Puma Biotechnology's Receivables - Other registered a high of $11.2 million during Q3 2018, and its lowest value of $1.2 million during Q4 2018.
  • In the last 2 years, Puma Biotechnology's Receivables - Other had a median value of $9.9 million in 2019 and averaged $7.4 million.